Published in Pharmacogenetics on May 01, 2004
Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol (2007) 1.78
The association of CYP2D6 genotype and postoperative nausea and vomiting in orthopedic trauma patients. Biol Res Nurs (2012) 0.81
Identification of CYP2D6 impaired functional alleles in Mexican Americans. Eur J Clin Pharmacol (2005) 0.80
How informative is a negative finding in a small pharmacogenetic study? Pharmacogenomics J (2011) 0.79
Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects. Br J Clin Pharmacol (2008) 0.78
ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res (2007) 5.75
Returning genetic research results to individuals: points-to-consider. Bioethics (2006) 2.01
Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J (2003) 1.75
Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses (2003) 1.67
Dual effects of rifampin on the pharmacokinetics of atrasentan. J Clin Pharmacol (2007) 1.64
High physician concern about malpractice risk predicts more aggressive diagnostic testing in office-based practice. Health Aff (Millwood) (2013) 1.27
Potential role of active vitamin D in retarding the progression of chronic kidney disease. Nephrol Dial Transplant (2006) 1.14
Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. Int J Neuropsychopharmacol (2009) 1.10
Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr (2004) 1.10
Barriers to HIV Care and Treatment Among Participants in a Public Health HIV Care Relinkage Program. AIDS Patient Care STDS (2015) 1.07
ru2hot?: A public health education campaign for men who have sex with men to increase awareness of symptoms of acute HIV infection. Sex Transm Infect (2013) 1.05
Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am J Nephrol (2007) 1.04
Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers. Epilepsy Res (2002) 1.01
Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients. Am J Nephrol (2009) 1.00
PhRMA white paper on ADME pharmacogenomics. J Clin Pharmacol (2008) 0.99
Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PhRMA-DruSafe Workshop. J Clin Pharmacol (2003) 0.96
A decision support system for cost-effective diagnosis. Artif Intell Med (2010) 0.95
Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin Pharmacol Ther (2006) 0.94
Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis. Am J Kidney Dis (2007) 0.93
Assessment of airway caliber and bronchodilator responsiveness in subjects with spinal cord injury. Chest (2005) 0.93
α7 nicotinic acetylcholine receptor (α7nAChR) expression in bone marrow-derived non-T cells is required for the inflammatory reflex. Mol Med (2012) 0.93
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res (2005) 0.91
Relationship of respiratory symptoms with smoking status and pulmonary function in chronic spinal cord injury. J Spinal Cord Med (2002) 0.90
Evidence for epistasis between SLC6A4 and a chromosome 4 gene as risk factors in major depression. Am J Med Genet B Neuropsychiatr Genet (2010) 0.89
Seroadaptation among men who have sex with men: emerging research themes. Curr HIV/AIDS Rep (2013) 0.89
Pharmacogenomic data submissions to the FDA: clinical case studies. Pharmacogenomics (2004) 0.89
Pharmacogenetics: improving drug and dose selection. Curr Opin Pharmacol (2008) 0.89
An open-label investigation into drug-drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjects. Clin Drug Investig (2015) 0.88
Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin. Hepatology (2005) 0.88
Trends in Serosorting and the Association With HIV/STI Risk Over Time Among Men Who Have Sex With Men. J Acquir Immune Defic Syndr (2016) 0.86
CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels. Clin Pharmacol Ther (2004) 0.86
Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study. Am J Cardiovasc Drugs (2010) 0.86
Hospital costs associated with smoking in veterans undergoing general surgery. J Am Coll Surg (2012) 0.85
A double-blind, randomized, placebo-controlled study of the dopamine D₃ receptor antagonist ABT-925 in patients with acute schizophrenia. J Clin Psychopharmacol (2011) 0.84
Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis. Pediatr Nephrol (2005) 0.83
The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor. Antivir Ther (2014) 0.83
Lack of correlation between SREBF1 genotype and hyperlipidemia in individuals treated with highly active antiretroviral therapy. AIDS (2003) 0.82
Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus. Cardiovasc Drugs Ther (2011) 0.82
A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4. Am J Nephrol (2006) 0.82
Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study. Cardiovasc Drugs Ther (2010) 0.81
Frequency of the frame-shifting CYP2D7 138delT polymorphism in a large, ethnically diverse sample population. Drug Metab Dispos (2007) 0.81
Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia: genetic screening is unnecessary. J Infect Dis (2006) 0.79
Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751. Pharmacogenet Genomics (2013) 0.78
Effect of ketoconazole on the pharmacokinetics of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 and its two active metabolites in healthy volunteers: population analysis of data from a drug-drug interaction study. Drug Metab Dispos (2013) 0.78
Changes in Condomless Sex and Serosorting Among Men Who Have Sex With Men After HIV Diagnosis. J Acquir Immune Defic Syndr (2016) 0.77
Development and regulatory strategies for drug and diagnostic co-development. Pharmacogenomics (2010) 0.76
Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies. Clin Cardiol (2010) 0.76
Regulatory sequences of orthologous petD chloroplast mRNAs are highly specific among Chlamydomonas species. Plant Mol Biol (2006) 0.76
Evaluation of the AERx pulmonary delivery system for systemic delivery of a poorly soluble selective D-1 agonist, ABT-431. Pharm Res (2002) 0.75
Prediction of successful weight reduction under sibutramine therapy. Pharmacogenetics (2004) 0.75
Comparison of In-Person Versus Telephone Interviews for Early Syphilis and Human Immunodeficiency Virus Partner Services in King County, Washington (2010-2014). Sex Transm Dis (2017) 0.75
Theranostics in veterinary medicine: where are we heading? Vet J (2009) 0.75
A Single Question to Examine the Prevalence and Protective Effect of Seroadaptive Strategies Among Men Who Have Sex With Men. Sex Transm Dis (2017) 0.75
A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease. Clin Ther (2013) 0.75
Effects of intravenous ABT-870 (iron (III)-hydroxide oligosaccharide) on mean arterial pressure and heart rate in the anaesthetized beagle: comparison with other iron-containing haematinic agents. Clin Exp Pharmacol Physiol (2005) 0.75
Effect of omeprazole on the pharmacokinetics of paricalcitol in healthy subjects. Biopharm Drug Dispos (2007) 0.75
Exposure-clinical response analysis of paricalcitol in patients with chronic kidney disease (stage 5) on hemodialysis or peritoneal dialysis. J Clin Pharmacol (2011) 0.75
Single- and multiple-ascending dose studies to evaluate the safety, tolerability, and pharmacokinetics of daclatasvir and asunaprevir in healthy male Japanese subjects. Int J Clin Pharmacol Ther (2015) 0.75
The effect of hepatic insufficiency on the safety and pharmacokinetics of paricalcitol (Zemplar). Nephron Clin Pract (2006) 0.75
Population pharmacokinetics of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 in healthy volunteers following single and multiple dose regimens. Biopharm Drug Dispos (2014) 0.75
Pharmacogenetics: an opportunity for codevelopment of pharmaceuticals and diagnostics. Expert Rev Mol Diagn (2002) 0.75
Evaluation of an Automated Express Care Triage Model to Identify Clinically Relevant Cases in a Sexually Transmitted Disease Clinic. Sex Transm Dis (2017) 0.75
Suggestive evidence on chromosomes 2 and 19 for HTR1A-independent linkage of genes to major depression. Neurogenetics (2009) 0.75
Modernizing Field Services for Human Immunodeficiency Virus and Sexually Transmitted Infections in the United States. Sex Transm Dis (2017) 0.75
Pharmacological and molecular characterization of a dorsal root ganglion cell line expressing cannabinoid CB(1) and CB(2) receptors. Eur J Pharmacol (2011) 0.75